Please login to the form below
Evrysdi
This page shows the latest Evrysdi news and features for those working in and with pharma, biotech and healthcare.
Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma
Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following ... Roche has priced Evrysdi by patient weight, with a maximum
Latest news
-
Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi
Evrysdi becomes the third drug approved to treat the condition and is the first that can be administered orally. ... Roche has priced Evrysdi by patient weight, with a maximum cost of $340, 000 per year, which is much less than its competitors.
-
Roche builds case for SMA drug risdiplam as FDA verdict nears
Outcome of FDA review due by 24 May
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
